Gaining Green

Today’s Hottest: Schweitzer-Mauduit International (NYSE:SWM), iBio (NYSEMKT:IBIO), TransEnterix (NYSEMKT:TRXC), OncoMed Pharmaceuticals (NASDAQ:OMED)

Manhattan Associates, Inc. (NASDAQ:MANH) shares fell -6.32% in last trading session and ended the day at $61.52. MANH Gross Margin is 57.70% and its has a return on assets of 34.10%. Manhattan Associates, Inc. (NASDAQ:MANH) quarterly performance is 10.73%.

On April 25, 2016, Dennis B. Story, Executive Vice President, Chief Financial Officer, and Treasurer, resigned from Manhattan Associates, Inc. (NASDAQ:MANH), effective June 30, 2016, to pursue personal and other business interests. Mr. Story served the Company for ten years. The Company is in the process of identifying a successor.

Schweitzer-Mauduit International Inc. (NYSE:SWM) ended the last trading day at $34.21. Company weekly volatility is calculated as 2.31% and price to cash ratio as 5.55. Schweitzer-Mauduit International Inc. (NYSE:SWM) showed a weekly performance of 4.62%.

Schweitzer-Mauduit International, Inc. (NYSE:SWM) will issue a press release announcing the Company`s first quarter 2016 results after the market closes on May 4, 2016 and hold a conference call to discuss results on May 5, 2016. SWM will use a presentation to accompany its conference call. The presentation can be found on the Company`s Web site in advance of the earnings conference call. The presentation can also be accessed via the earnings conference call webcast.

On 28 April, iBio, Inc. (NYSEMKT:IBIO) shares fell -3.89% and was closed at $0.71. IBIO EPS growth in last 5 year was 16.10%. iBio, Inc. (NYSEMKT:IBIO) year to date (YTD) performance is 26.79%.

TransEnterix, Inc. (NYSEMKT:TRXC) shares fell -8.43% in last trading session and ended the day at $1.63. TRXC has a return on assets of -23.00%. TransEnterix, Inc. (NYSEMKT:TRXC) quarterly performance is -46.03%.

TransEnterix, Inc. (NYSEMKT:TRXC) announcing that the United States Food and Drug Administration (“FDA”) notified the Company on April 19, 2016 that the FDA has determined that the SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) caters to the Healthcare space. Its weekly performance is 8.39%. On the last day of trading company shares ended up at $13.57. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) distance from 50-day simple moving average (SMA50) is 29.67%.

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.